Compare iShares Semiconductor ETF (SOXX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Semiconductor ETF vs Viatris Inc — how do they compare? iShares Semiconductor ETF trades at $559.82 (market cap $48.19B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: iShares Semiconductor ETF is far larger — about 2.4× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while iShares Semiconductor ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Semiconductor ETF for 46 Days and Viatris Inc for 57 Days on average.
| SOXX | VTRS | |
|---|---|---|
Market Cap | $48.19B | $20.03B |
Volume | 10,257,578 | 14,109,977 |
Sector | Sector/Thematic | Health |
52-Week High | $655.01 | $18.27 |
52-Week Low | $268.10 | $9.74 |
Typical Hold Time | 46 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXX trades at $559.40, down 4.04% over the past 24 hours amid broader semiconductor sector volatility. The ETF maintains a bullish technical signal with strong moving average support, while oscillators show neutral momentum. Recent news highlights continued AI-driven semiconductor demand with projections of market growth to $2.3 trillion by 2030, though concerns about valuation premiums and Michael Burry's expanded short positions create mixed sentiment.
The semiconductor sector faces a critical juncture with AI infrastructure demand driving earnings growth while elevated valuations present headwinds. SOXX's fundamental strength depends on continued chip industry expansion, though concentration risk and potential market rotation pose significant challenges for near-term performance.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
